CBER’s Experience With Adaptive Design Clinical Trials
- 1 March 2016
- journal article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 50 (2) , 195-203
Abstract
There is considerable interest among pharmaceutical and other medical product developers in adaptive clinical trials, in which knowledge learned during the course of a trial affects ongoing conduct or analysis of the trial. When the FDA released a draft Guidance document on adaptive design clinical trials in early 2010, expectations were high that it would lead to an increase in regulatory submissions involving adaptive design features, particularly for confirmatory trials. A 6-year (2008-2013) retrospective survey was performed within the Center for Biologics Evaluation and Research (CBER) at the FDA to gather information regarding the submission and evaluation of adaptive design trial proposals. We present an up-to-date summary of adaptive design proposals seen in CBER and provide an overview of our experiences. We share our concerns regarding the statistical issues and operational challenges raised during the review process for adaptive design trials. We also provide general recommendations for developing proposals for such trials. Our motivation in writing this paper was to encourage the best study design proposals to be submitted to CBER. Sometimes these can be adaptive, and sometimes a simpler design is most efficient.Keywords
This publication has 30 references indexed in Scilit:
- Adaptive trial designs: a review of barriers and opportunitiesTrials, 2012
- Barriers and opportunities for implementation of adaptive designs in pharmaceutical product developmentClinical Trials, 2010
- Sample Size Re-Estimation for Adaptive Sequential Design in Clinical TrialsJournal of Biopharmaceutical Statistics, 2008
- Adaptive design methods in clinical trials – a reviewOrphanet Journal of Rare Diseases, 2008
- Evaluating the safety of a rotavirus vaccine: the REST of the storyClinical Trials, 2008
- Increasing the sample size when the unblinded interim result is promisingStatistics in Medicine, 2004
- Admissible two‐stage designs for phase II cancer clinical trialsStatistics in Medicine, 2004
- On the inefficiency of the adaptive design for monitoring clinical trialsBiometrika, 2003
- Exact power and sample size for vaccine efficacy studiesCommunications in Statistics - Theory and Methods, 1998
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989